Hennion & Walsh Asset Management’s Immunogen Inc IMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-356,997
Closed -$10.6M 895
2023
Q4
$10.6M Sell
356,997
-166,077
-32% -$3.31M 0.6% 22
2023
Q3
$8.3M Buy
523,074
+7,795
+2% +$130K 0.53% 27
2023
Q2
$9.72M Buy
515,279
+34,542
+7% +$408K 0.58% 23
2023
Q1
$1.85M Buy
480,737
+11,100
+2% +$47.3K 0.11% 222
2022
Q4
$2.33M Buy
469,637
+136,763
+41% +$742K 0.14% 181
2022
Q3
$1.59M Buy
332,874
+23,540
+8% +$124K 0.1% 229
2022
Q2
$1.39M Buy
309,334
+113,188
+58% +$492K 0.09% 251
2022
Q1
$934K Buy
196,146
+77,427
+65% +$429K 0.05% 362
2021
Q4
$881K Buy
+118,719
New +$738K 0.04% 399

Other funds holding IMGN

Hennion & Walsh Asset Management's IMGN Position: Q1 2024 in Review

Hennion & Walsh Asset Management sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 356,997 shares — an estimated $10.6M sold.

Hennion & Walsh Asset Management first reported a position in IMGN in Q4 2021 and held it in 9 quarters. The position peaked at $10.6M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Hennion & Walsh Asset Management reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 356,997 Immunogen Inc shares in Q1 2024, an estimated $10.6M.
  • Hennion & Walsh Asset Management first reported a position in Immunogen Inc in Q4 2021 and held it in 9 quarters.
  • Hennion & Walsh Asset Management's Immunogen Inc position peaked at $10.6M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q1 2024, filed 17 Apr 2024.